Illumina, Inc.
ILMNHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeIllumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. At a $40.68B market cap, Illumina, Inc. ranks as a large-cap company within healthcare. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Market Cap
$40.68B
Beta
1.42
P/E (TTM)
50.26
P/E (Fwd)
43.98
EPS (TTM)
$5.36
EPS (Fwd)
$6.13
ROE
32.3%
ROA
8.7%
Cash
$1.17B
Total Debt
$2.53B
Free CF
$797.6M
52W Change
168.5%
Annual Financials
Cash vs Debt
Where ILMN stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, ILMN finished 55.60% above its 150-day moving average ($177.81) and 65.70% above its 200-day moving average ($166.97). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ILMN overbought or oversold?
At the October 13, 2026 close, ILMN's RSI(14) was 62.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $1.17B in cash, though total debt stands at $2.53B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $797.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 32.3% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $4.58B (2022) to $4.34B (2025).
At over 50x earnings, ILMN carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing ILMN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.